S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

Authors: H. Erba, P. Montesinos, R. Vrhovac, E. Patkowska, H.-J. Kim, P. Zak, P.-N. Wang, T. Mitov, J. Hanyok, L. Liu, A. Benzohra, A. Lesegretain, J. Cortes, A. Perl, M. Sekeres, H. Dombret, S. Amadori, J. Wang, M. Levis, R. Schlenk

Published: 2022-06-23

DOI: 10.1097/01.hs9.0000843296.73803.85

Source: Full article

---

Abstract

No abstract found.